Skip to main contentSkip to navigation
Sirius Investors
Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.

CMOPF
OTCHealthcare

Cosmo Pharmaceuticals N.V. (CMOPF) Investment Research Dashboard

About Cosmo Pharmaceuticals N.V. (CMOPF) stock analysis

Get live CMOPF stock price $77.30, comprehensive Cosmo Pharmaceuticals N.V. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time CMOPF stock data and investment insights.

77.30
0.32%Today
Market Cap
1.33B
Volume
4
52W High
169.90
52W Low
75.00

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system t...

Company Information

CEO
Giovanni di Napoli
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
324

Contact Information

Address
Riverside 2
Country
IE

Investment Analysis & Business Insights

Healthcare
Medical - Pharmaceuticals

Investment Highlights

Strong presence in the Healthcare sector with established market position

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Cosmo Pharmaceuticals N.V. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Cosmo Pharmaceuticals N.V.
  • Investors should consider how Cosmo Pharmaceuticals N.V. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

1.33B

P/E Ratio (TTM)

-291.32

Beta

0.82

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

80/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+5.7%+6.1%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
86/100⭐⭐⭐⭐⭐
Healthcare+0.7%+3.3%+3.5%24.1
80/100⭐⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
56/100⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
56/100⭐⭐⭐⭐
Real Estate-0.5%-0.1%-1.6%29.2
43/100⭐⭐⭐
Energy-2.1%-5.8%-5.1%19.1
39/100⭐⭐
Utilities-1.0%-3.0%-5.9%26.8
28/100⭐⭐
Industrials+0.6%+1.7%-11.2%30.1
26/100⭐⭐
Consumer Cyclical+0.5%-0.4%-6.3%43.0
21/100
Technology+0.6%-2.3%-9.6%40.7
17/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.